Novo Nordisk (NOVA) Stock Forecast & Price Target

Compare

134 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NOVA Analyst Ratings

Moderate Buy

4 Buy

3 Hold

1 Sell

Based on 8 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NOVA Stock 12 Month Forecast

Average Price Target

€49.01

▲(4.05% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is €49.01 with a high forecast of €59.71 and a low forecast of €40.09. The average price target represents a 4.05% change from the last price of €47.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"€39","122":"€122","59.75":"€59.8","80.5":"€80.5","101.25":"€101.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":59.7114231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€59.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":49.0060179585,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€49.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.09195551,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€40.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,59.75,80.5,101.25,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.1,49.91626331538462,50.73252663076923,51.548789946153846,52.36505326153846,53.18131657692308,53.99757989230769,54.81384320769231,55.63010652307692,56.446369838461536,57.26263315384615,58.07889646923077,58.89515978461538,{"y":59.7114231,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.1,49.09277061219231,49.08554122438462,49.07831183657692,49.07108244876923,49.06385306096154,49.05662367315385,49.04939428534615,49.04216489753846,49.03493550973077,49.02770612192308,49.020476734115384,49.01324734630769,{"y":49.0060179585,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.1,48.40707350076923,47.714147001538464,47.02122050230769,46.32829400307693,45.635367503846155,44.94244100461538,44.24951450538462,43.556588006153845,42.86366150692308,42.17073500769231,41.477808508461536,40.78488200923077,{"y":40.09195551,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":121.545,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.901,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.471,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.451,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.553,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.788,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.885,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.103,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.738,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.333,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.567,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€59.71

Average Price Target€49.01

Lowest Price Target€40.09

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Thibault Boutherin

Morgan Stanley

€50.33→€40.09

Sell

-14.88%

Downside

Downgraded

09/29/25

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO) and Sanofi (Other OTC: SNYNF)Novo Nordisk A/S (NVO.N) downgraded from Equal-weight to Underweight with a price target reduction from US$59.00 to US$47.00.

Veda Pharmyne

TR | OpenAI - 4o

€53.74→€52.89

Buy

12.29%

Upside

Reiterated

09/26/25

AI Generated ArticleAI Generated Article

Evan Seigerman

BMO Capital

€42.65

Hold

-9.45%

Downside

Reiterated

09/18/25

BMO Capital Sticks to Their Hold Rating for Novo Nordisk (NVO)We remain Market Perform on NVO shares.

Kerry Holford

Berenberg Bank

€81.72→€56.94

Buy

20.89%

Upside

Upgraded

09/17/25

Positive Report for Novo Nordisk (NVO) from Berenberg Bank

Simon Baker CFA

Redburn Atlantic

―

Buy

―

Upgraded

09/16/25

Novo Nordisk (NVO) was upgraded to a Buy Rating at Redburn Atlantic

Florent Cespedes

Bernstein

―

Buy

―

Upgraded

09/09/25

Novo Nordisk upgraded to Outperform from Market Perform at BernsteinNovo Nordisk upgraded to Outperform from Market Perform at Bernstein

Michael Nedelcovych

TD Cowen

€89.57→€59.71

Buy

26.78%

Upside

Reiterated

08/19/25

Novo Nordisk's Strategic Focus on Obesity Market and Oral Semaglutide Drives Buy Rating

Peter Verdult

Exane BNP Paribas

€46.06

Hold

-2.20%

Downside

Upgraded

08/13/25

Novo Nordisk upgraded to Neutral from Underperform at BNP Paribas ExaneNovo Nordisk upgraded to Neutral from Underperform at BNP Paribas Exane

Rajesh Kumar

HSBC

€48.62

Hold

3.23%

Upside

Downgraded

07/31/25

Novo Nordisk downgraded to Hold from Buy at HSBCNovo Nordisk downgraded to Hold from Buy at HSBC

Jasper Hellweg

Argus Research

€93.83→€76.77

Buy

63.00%

Upside

Reiterated

06/18/25

Novo Nordisk (NVO) Gets a Buy from Argus Research

Seamus Fernandez

Guggenheim

―

Hold

―

Downgraded

04/17/25

Novo Nordisk downgraded to Neutral from Buy at GuggenheimNovo Nordisk downgraded to Neutral from Buy at Guggenheim

Sachin Jain

Bank of America Securities

€121.91

Buy

158.84%

Upside

Reiterated

03/28/25

Confident Buy Rating for Novo Nordisk Amid Sales Guidance Adjustments and Market Challenges

Unknown Analyst

Stifel Nicolaus

Not Ranked

Stifel Nicolaus

―

Hold

―

Downgraded

03/03/25

Wan Nurhayati

CFRA

€104.07→€76.77

Hold

63.00%

Upside

Reiterated

01/21/25

Novo Nordisk (NVO) PT Lowered to $90 at CFRACFRA analyst Wan Nurhayati lowered the price target on Novo Nordisk (NYSE: NVO) to $90.00 (from $122.00) while maintaining a Hold rating.

James Quigley

Goldman Sachs

€126.25→€105.77

Buy

124.57%

Upside

Reiterated

01/13/25

Novo Nordisk (NVO) PT Lowered to $124 at Goldman SachsGoldman Sachs analyst James Quigley lowered the price target on Novo Nordisk (NYSE: NVO) to $124.00 (from $148.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Thibault Boutherin

Morgan Stanley

€50.33→€40.09

Sell

-14.88%

Downside

Downgraded

09/29/25

Veda Pharmyne

TR | OpenAI - 4o

€53.74→€52.89

Buy

12.29%

Upside

Reiterated

09/26/25

AI Generated ArticleAI Generated Article

Evan Seigerman

BMO Capital

€42.65

Hold

-9.45%

Downside

Reiterated

09/18/25

BMO Capital Sticks to Their Hold Rating for Novo Nordisk (NVO)We remain Market Perform on NVO shares.

Kerry Holford

Berenberg Bank

€81.72→€56.94

Buy

20.89%

Upside

Upgraded

09/17/25

Positive Report for Novo Nordisk (NVO) from Berenberg Bank

Simon Baker CFA

Redburn Atlantic

―

Buy

―

Upgraded

09/16/25

Novo Nordisk (NVO) was upgraded to a Buy Rating at Redburn Atlantic

Florent Cespedes

Bernstein

―

Buy

―

Upgraded

09/09/25

Novo Nordisk upgraded to Outperform from Market Perform at BernsteinNovo Nordisk upgraded to Outperform from Market Perform at Bernstein

Michael Nedelcovych

TD Cowen

€89.57→€59.71

Buy

26.78%

Upside

Reiterated

08/19/25

Novo Nordisk's Strategic Focus on Obesity Market and Oral Semaglutide Drives Buy Rating

Peter Verdult

Exane BNP Paribas

€46.06

Hold

-2.20%

Downside

Upgraded

08/13/25

Novo Nordisk upgraded to Neutral from Underperform at BNP Paribas ExaneNovo Nordisk upgraded to Neutral from Underperform at BNP Paribas Exane

Rajesh Kumar

HSBC

€48.62

Hold

3.23%

Upside

Downgraded

07/31/25

Novo Nordisk downgraded to Hold from Buy at HSBCNovo Nordisk downgraded to Hold from Buy at HSBC

Jasper Hellweg

Argus Research

€93.83→€76.77

Buy

63.00%

Upside

Reiterated

06/18/25

Novo Nordisk (NVO) Gets a Buy from Argus Research

Seamus Fernandez

Guggenheim

―

Hold

―

Downgraded

04/17/25

Novo Nordisk downgraded to Neutral from Buy at GuggenheimNovo Nordisk downgraded to Neutral from Buy at Guggenheim

Sachin Jain

Bank of America Securities

€121.91

Buy

158.84%

Upside

Reiterated

03/28/25

Confident Buy Rating for Novo Nordisk Amid Sales Guidance Adjustments and Market Challenges

Unknown Analyst

Stifel Nicolaus

Not Ranked

Stifel Nicolaus

―

Hold

―

Downgraded

03/03/25

Wan Nurhayati

CFRA

€104.07→€76.77

Hold

63.00%

Upside

Reiterated

01/21/25

Novo Nordisk (NVO) PT Lowered to $90 at CFRACFRA analyst Wan Nurhayati lowered the price target on Novo Nordisk (NYSE: NVO) to $90.00 (from $122.00) while maintaining a Hold rating.

James Quigley

Goldman Sachs

€126.25→€105.77

Buy

124.57%

Upside

Reiterated

01/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

1 Month

xxx

Success Rate

10/18 ratings generated profit

Average Return

-0.21%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of -0.21% per trade.

3 Months

xxx

Success Rate

12/24 ratings generated profit

Average Return

+0.34%

reiterated a xxx

rating 6 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +0.34% per trade.

1 Year

Sachin JainBank of America Securities

Success Rate

8/24 ratings generated profit

Average Return

-4.68%

reiterated a buy rating 6 months ago

Copying Sachin Jain's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.68% per trade.

2 Years

xxx

Success Rate

4/18 ratings generated profit

Average Return

-14.47%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -14.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NOVA Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NOVA has received 17 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. NOVA average Analyst price target in the past 3 months is 49.01.

Each month's total comprises the sum of three months' worth of ratings.

NOVA Financial Forecast

NOVA Earnings Forecast

Next quarter’s earnings estimate for NOVA is €0.70 with a range of €0.54 to €0.87. The previous quarter’s EPS was €0.79. NOVA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year NOVA has Preformed in-line its overall industry.

NOVA Sales Forecast

Next quarter’s sales forecast for NOVA is €10.29B with a range of €10.01B to €10.59B. The previous quarter’s sales results were €9.97B. NOVA beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year NOVA has Preformed in-line its overall industry.

NOVA Stock Forecast FAQ

What is DE:NOVA’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 49.01.

What is DE:NOVA’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 4.05% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 3 hold ratings and 1 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 49.01. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €59.71 ,and the lowest forecast is €40.09. The average share price target represents 4.05% Increase from the current price of €47.1.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of DE:NOVA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novo Nordisk (NOVA) Stock Forecast & Price Target

NOVA Analyst Ratings

NOVA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NOVA Analyst Recommendation Trends

NOVA Financial Forecast

NOVA Earnings Forecast

NOVA Sales Forecast

NOVA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts